The patient-led Global Myeloma Action Network (GMAN) recently designated March 30 as International Myeloma Action Day to raise awareness of multiple myeloma,…
Articles by Inês Martins, PhD
The first-ever Multiple Myeloma Research Foundation (MMRF) Patient Summit was held March 25 in Denver to help patients…
Antibody-drug conjugates (ADCs), a class of drugs in which a cancer-targeting therapy is attached to a specific monoclonal antibody without…
By activating the immune system, the experimental drug LCL161 has the potential to fight myeloma in both mice and humans, according…
The cancer charity Myeloma UK has launched a Phase 1 clinical trial testing Reolysin (pelareorep), a modulator of the immune system…
Don Wright, who recently finished his 100th marathon while on active treatment for multiple myeloma, will continue running, but now…
Multiple myeloma patients undergoing autologous stem cell transplants (ASCT) may strongly benefit from SELLAS‘ WT-1 cancer vaccine, galinpepimut-S, according…
GlycoMimetics will present preclinical research at the American Association for Cancer Research (AACR) Annual Meeting 2017, demonstrating the…
Celyad is ready to enroll patients in its Phase 1 THINK trial in Rosewell Park, N.Y. and the University of Pittsburgh Medical…
Patients with relapsed or refractory multiple myeloma who receive a combination of Kyprolis (carfilzomib) and dexamethasone have significantly better survival rates than…